The course of chronic myeloid leukemia (CML) has changed since the introduction of imatinib, and its side-effects are still being reported. We are reporting a case of a CML patient who presented to us with discoloration of the upper front teeth following 6 months of therapy with imatinib. On detailed evaluation, the patient was found to have imatinib-induced dental hyperpigmentation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689028 | PMC |
| http://dx.doi.org/10.4103/0253-7613.169576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two cases of imatinib induced oral pigmentation affecting the palate.
Oral Surg Oral Med Oral Pathol Oral Radiol
October 2024
Attending, Oral and Maxillofacial Pathology Residency Program, Section of Oral Pathology, New York-Presbyterian Queens, Flushing, NY.
Background: Medication-related oral pigmentation is a unique yet benign finding in the dental setting. As new antineoplastic agents emerge, it is likely that this documented manifestation will continue to grow.
Case Description: Here, we describe two case presentations of imatinib-related hyperpigmentation of the palate.
A case of imatinib-related obstructive bronchiolitis followed long term.
Respir Med Case Rep
April 2020
Department of Respiratory Medicine, Tokyo Medical University, Tokyo, Japan.
Obstructive bronchiolitis (OB) is an intractable disease causing stenosis in the surrounding bronchiolar region and bronchiolar lumen obstruction. Causes of OB are lung and hematopoietic stem-cell transplantation, collagen diseases, infections, and foods, but there are very few reports of drug-induced OB [1]. Imatinib is a drug used for the treatment of leukemia, gastrointestinal stromal tumors, etc.
View Article and Find Full Text PDFImatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.
Int J Dermatol
July 2018
Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Background: Imatinib mesylate is a tyrosine-kinase inhibitor used as the first-line treatment in chronic myeloid leukemia patients, but it is also indicated for other hematological diseases and solid tumors. Imatinib treatment is often associated with hypopigmentation, but only a few cases of hyperpigmentation are described in literature.
Methods: We are reporting the first case of imatinib-related hyperpigmentation involving the oral mucosa, skin, and nails in a patient affected by chronic myeloid leukemia and treated with imatinib since 2002.
Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female.
Indian J Pharmacol
October 2016
Department of Medicine, S N Medical College, Agra, Uttar Pradesh, India.
The course of chronic myeloid leukemia (CML) has changed since the introduction of imatinib, and its side-effects are still being reported. We are reporting a case of a CML patient who presented to us with discoloration of the upper front teeth following 6 months of therapy with imatinib. On detailed evaluation, the patient was found to have imatinib-induced dental hyperpigmentation.
View Article and Find Full Text PDFA Rare Case of Melanosis of the Hard Palate Mucosa in a Patient with Chronic Myeloid Leukemia.
Case Rep Dent
October 2015
Department of Radiological, Oncological and Anatomo-Pathological Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a good quality of life. Despite its beneficial effects, Imatinib has significant side effects such as mucosal pigmentation. A 72-year-old female having an Imatinib induced mucosal pigmentation is presented: she has been treated with Imatinib since 2003 and only in 2014 discovered, during a routine dental visit, having a pigmented lesion on her hard palate mucosa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!